ATI Obligations Sample Clauses

ATI Obligations. The ATI agrees that it shall: 10.1. maintain an advisory structure to maintain and refresh the Strategy; 10.2. publish the timetable of the Strategic Review Committee meetings in such format and within such timescales as it shall reasonably determine; 10.3. use all reasonable but commercially prudent endeavours to provide feedback to Lead Project Partners on proposed Projects without unreasonable delay following the relevant Strategic Review Committee meeting to discuss the Project (providing always that it shall not be obliged to provide any feedback until it has received all relevant information from the Strategic Review Committee and any other relevant party and has had the reasonable opportunity to review and process the same); 10.4. use all reasonable but commercially prudent endeavours to work with each Organisation in a fair and reasonable manner in the development of Project proposals; 10.5. comply with the charter of trust set out in Appendix 2, as amended from time to time by the ATI’s board; 10.6. notify each Organisation in writing if there is a change of control of the ATI (within the meaning of section 1124 of the Corporation Tax Act 2010) and/or the members of the ATI’s board of directors; 10.7. confirm upon the written request of an Organisation whether an entity is a party to this Framework Agreement as an Organisation; 10.8. obtain and maintain such insurance policies as the board of the ATI in its sole discretion deems necessary or advantageous for the ATI; and 10.9. maintain and publish its Strategy on such terms and in such format as it determines.

ATI Obligations. As part of and in accordance with the R&D Program, ATI shall use Commercially Reasonable Efforts (directly or through one or more of its Affiliates or by permitted subcontracting hereunder), and in a manner consistent with, and subject to, the Research Plan and the direction of the JRC: (i) to generate compositions of matter in the Product Form for each Program, including molecular drug design and generation of applicable Adnectin chemistry; (ii) to conduct certain preclinical development activities including, by way of example, assays for activity, toxicology, biophysical properties, pharmacokinetics, and in vitro and in vivo testing of a Licensed Compound. (iii) to conduct process development, develop release assay methods, and preclinical and clinical manufacturing of Licensed Compounds as set forth in Article 6; and (iv) to commit at least such number of ATI FTEs to the Programs, in the aggregate, as are being funded by BMS pursuant to Section 9.2(a) and 9.2(e) to the activities described in clauses (i) through (iii) above.